New predictors of survival for early-stage NSCLC.

摘要

Ribonucleotide reductase M1 poly-peptide (RRM1) and excision repair cross-complementation group 1 (ERCC1) protein concentrations can help predict survival of patients with surgically treated early-stage non-small-cell lung cancer (NSCLC), say US researchers (N Engl J Med 2007; 356: 800-08). The group assessed 187 patients with early-stage NSCLC who had surgical resection only. An automated quantitative determination method measured expression of RRM1 and two other proteins related to NSCLC: ERCC1 and the phosphatase and tensin homologue (PTEN). "We were working on the development of a reliable and objective method to detect RRM1 in routinely collected biospecimens and not in specimens that required a high-tech research environment, and finally we succeeded", says author Gerald Bepler (H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA).